At a glance
| What it is | Cosmetic ingredient, a collagen-inspired signal peptide (part of Matrixyl 3000) |
| FDA status | Does not require FDA approval, as a cosmetic ingredient rather than a drug |
| Research | Activity rests on laboratory and manufacturer data; independent single-ingredient human evidence is lacking |
| Used in | "Anti-aging" products for the look of firmness and fine lines |
| Evidence strength | Low research |
What is palmitoyl tripeptide-1?
Palmitoyl tripeptide-1 is a peptide of three amino acids (glycine, histidine, and lysine) joined to palmitic acid, a fatty acid added to help the peptide pass into skin. The peptide portion is a natural fragment released from collagen, so it acts as a familiar signal to skin cells. It is made by Sederma and is one of the two active peptides in the widely used Matrixyl 3000 blend. It is a cosmetic ingredient, not a drug.
How does it work?
Laboratory studies describe palmitoyl tripeptide-1 as a matrikine, a peptide that signals skin cells to rebuild support structures. In cell models it is reported to prompt dermal fibroblasts to produce more collagen (types I and III) and fibronectin, the proteins that keep skin looking firm and smooth. The attached fatty acid is included to improve how well the peptide penetrates the skin surface. These are laboratory and manufacturer findings about how the peptide behaves, not proof of a clinical result. In finished cosmetics the benefit is described in appearance terms, such as the look of firmer skin and reduced fine lines.
Is it FDA-approved?
No, and it does not need to be. The FDA does not pre-approve cosmetic ingredients. A cosmetic may describe effects on the look and feel of skin, while a claim to rebuild the body's collagen would make a product a drug. Palmitoyl tripeptide-1 is used within the cosmetic boundary, for the appearance of the skin.
What is it used for?
Palmitoyl tripeptide-1 is used in "anti-aging" serums and creams, almost always alongside palmitoyl tetrapeptide-7 as the Matrixyl 3000 pairing. The appearance goals are the look of firmer, plumper skin and a reduction in the appearance of fine lines and wrinkles.
What does the research show?
The direct human evidence is limited:
- According to PubMed, the peptide appears in a human study of a multi-peptide eye serum that reported appearance benefits, but because many peptides were combined, the effect cannot be attributed to palmitoyl tripeptide-1 alone.
- Most of the specific efficacy data come from manufacturer in-use panels.
- An independent review notes that collagen-fragment peptides like this one penetrate skin poorly, which is a relevant real-world limitation.
- There is no independent single-ingredient human trial.
What are the side effects?
Palmitoyl tripeptide-1 is generally considered well tolerated on the skin, with low irritation potential at cosmetic use levels. As with any new product, a patch test is reasonable for sensitive or reactive skin, since individual responses vary.
Evidence strength
Low research: Support rests on laboratory and manufacturer data plus a confounded multi-peptide study, with no sound independent human trial of the ingredient by itself.
Sources: a clinical study of a multi-peptide eye serum (Li et al., Journal of Cosmetic Dermatology, 2023, DOI: 10.1111/jocd.15849); and a review of peptide skin permeability (Mortazavi and Moghimi, International Journal of Cosmetic Science, 2022, DOI: 10.1111/ics.12770), both indexed on PubMed. This document is educational and does not constitute medical advice.
Heart & Vascular Health
Metabolic Health
Energy
Liver Health
Kidney
Sex Hormones
Thyroid Health
Nutrients
Immune System
Inflammation